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To determine accuracy of measures of deaths attri-
butable to Clostridium difﬁ  cile infection, we compared 
3 measures for 2007–2008 in Ontario, Canada: death 
certiﬁ   cate; death within 30 days of infection; and panel 
review. Data on death within 30 days were more feasible than 
panel review and more accurate than death certiﬁ  cate data.
C
lostridium difﬁ  cile infection (CDI) has emerged as 
a major health care–associated infection; incidence, 
hospitalizations, and mortality rates are increasing (1,2). 
Reported case-fatality rates are 6%–30% and seem to be 
rising (3,4). The reporting of CDI-associated deaths could 
be considered a quality indicator; however, the accuracy of 
death certiﬁ  cate data is questionable (5). We analyzed CDI 
deaths in 3 hospitals in Ontario, Canada, and compared 3 
measures for attributing death to CDI: death certiﬁ  cate, 
death within 30 days of CDI, and a panel review process 
(considered the reference standard).
The Study
From April 2007 through February 2008, as independent 
quality initiatives, 3 hospitals in Ontario reviewed deaths 
among patients with CDI infection. Patients were identiﬁ  ed 
by using existing surveillance data. To calculate the time 
from CDI diagnosis to death, we compared date of death 
with date of onset of CDI symptoms or date of the positive 
C. difﬁ  cile test result if symptom onset was unclear. For 
recurrent CDI, date of recurrent symptoms nearest to date 
of death was considered. Patients with suggestive recurrent 
symptoms but no laboratory conﬁ  rmation were included in 
a further analysis in this study.
For panel review, clinical data and cause of death 
indicated on death certiﬁ   cate were anonymously 
summarized for each patient. Each case summary was 
reviewed by 3 physicians with varying levels of expertise 
with CDI. Panel members were asked to independently 
categorize their interpretation as follows: a) death was 
directly attributable to CDI; b) CDI strongly contributed 
to death; c) CDI somewhat contributed to death; d) death 
was unrelated to CDI; or e) information was insufﬁ  cient to 
determine the role of CDI in the death. Hospital A was the 
ﬁ  rst facility to undertake a panel review and included only 
4 categories (category b was excluded). Feedback from 
reviewers at hospital A led to development of category b.
After individually classifying each death, reviewers 
participated in a panel discussion to achieve consensus. 
For analysis, the 5 categories were subsequently collapsed 
into 3: CDI directly caused or strongly contributed to death; 
CDI somewhat contributed to death or was unrelated to 
death; and information was insufﬁ  cient to determine the 
role of CDI in the death.
The  κ statistic was used to determine the level of 
agreement on cause of death between death certiﬁ  cate 
and panel review. The 3 categories listed above were 
compared with the following death certiﬁ  cate categories: 
CDI, enterocolitis, or toxic megacolon as primary or 
contributory cause of death; death unrelated to CDI; and 
missing information.
The percentage agreement of death within 30 days 
of CDI and panel review consensus was calculated by 
using combined data from hospitals A and B. Hospital 
C was excluded from this analysis because only patients 
who died within 30 days of CDI diagnosis were included 
in that review. At hospital B, because data on individual 
physician assignment of categories were available, inter-
rater reliability was analyzed by using the Fleiss κ statistic.
CDI was diagnosed for 501 patients, and 188 CDI 
patients died. Of these, 120 (64%) patients died within 30 
days of CDI. The 30-day case-fatality ratios for hospitals 
A, B, and C were 20% (25/124), 35% (62/177), and 16% 
(33/200), respectively.
Panel reviews were conducted for all 31 in-hospital 
deaths in hospital A, 90 deaths in Hospital B, but only 
30 of the deaths that occurred within 30 days of CDI 
diagnosis in hospital C. Among the 151 deaths included in 
the panel review process, CDI directly caused or strongly 
contributed to the death for 101 (67%) and somewhat 
contributed or was unrelated to death for 49 (32%). For 1 
patient, information was insufﬁ  cient for determining cause 
of death. Where data were available (hospital B), inter-
rater reliability among panel members was satisfactory (κ 
= 0.71, 95% CI 0.59–0.83).
According to death certiﬁ   cate data, CDI was the 
primary cause of death for 7 (5%) patients and a contributory 
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by panel review as strongly attributable to CDI, 37 were 
classiﬁ  ed by death certiﬁ  cate as having CDI as primary/
secondary cause (Table 1). When panel review data were 
compared with death certiﬁ  cate data, κ was 0.07 (95% CI 
0.05–0.20), indicative of poor agreement. The exclusion 
of hospital A, where deaths were originally classiﬁ  ed into 
only 4 categories, did not alter the observed κ scores (κ = 
0.04, 95% CI 0.09–0.17).
To compare the proportion of in-hospital deaths 
within 30 days with results of the panel review, we used 
only data from hospitals A and B because hospital C data 
only included patients who had died within 30 days. The 
panel concluded that CDI directly or strongly contributed 
to death within 30 days of onset for 80% (63/79) of 
patients (Table 2). If cases suggestive of recurrent CDI 
(not conﬁ  rmed by testing) were included, this percentage 
rose to 86% (68/79). When panel review was used as 
the reference standard, the sensitivity of death within 30 
days of CDI onset was 80%, speciﬁ  city 41%, and positive 
predictive value 72%.
Conclusions
Agreement between causes of deaths categorized by 
review panel and causes listed on death certiﬁ  cates is poor. 
Ontario’s vital statistics system currently codes only 1 
cause of death, limiting the ability to identify deaths for 
which CDI might have been a contributing cause. These 
shortcomings suggest that death certiﬁ  cate data may be 
inaccurate for assigning CDI-attributable death.
Panel review of all deaths is an alternative approach 
that would enable clinical analysis of the circumstances 
surrounding the death. A panel review reduces individual 
reviewer bias; however, while arguably the most accurate 
method of determining cause of death other than autopsy, it 
is not feasible for wide-scale public reporting.
Our study supports the use of death within 30 days as 
a marker for CDI-attributable death because 80% of deaths 
identiﬁ  ed by panel review as being directly or strongly 
attributable to CDI occurred within 30 days of diagnosis. 
This percentage increased to 86% if clinical recurrences 
were included. Compared with panel review, death within 
30 days had reasonable sensitivity (80%) and positive 
predictive value (72%) but, as expected, was not speciﬁ  c 
(41%). Capturing data on death within 30 days would be 
more feasible than panel review and more accurate than 
death certiﬁ  cate data. However, data on death within 30 
days could not be used to determine the contribution of 
CDI to any patient’s death.
Our study has a few limitations. Because data were 
derived from 3 hospitals that undertook reviews for different 
purposes, the slight differences in inclusion criteria and 
death categorizations necessitated subanalyses for the 
death within 30 days comparison and the collapsing of the 
categorizations into 3 groups. Data quality also has inherent 
problems associated with retrospective chart audits because 
of limitations in the documentation of clinical events. 
Finally, we acknowledge that categorization of deaths by 
panel review is a subjective process based on interpretation 
of the clinical case summaries and expert opinion.
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Table 1. Proportion of deaths attributable to CDI, by panel review coding and death certificate classification, Ontario, Canada, April 
2007–February 2008* 
Reference category  
Death certificate, no. (%) 
Panel
review, no.†
CDI as primary 
cause of death
CDI as primary or 
secondary cause of death
CDI as unrelated 
cause of death
Missing
information
Directly/strongly attributable to CDI 6 (6) 37 (37) 61 (60) 3 (3) 101
Somewhat/unrelated to CDI 1 (2) 14 (29) 35 (71) 0 49
Insufficient information 0 0 1 (100) 0 1
Total 7 (5) 51 (34) 97 (64) 3 (2) 151
*CDI, Clostridium difficile infection. 
†Categories determined by panel review. Because panel review was considered the reference standard, panel review percentages = 100%. 
Table 2. Proportion of deaths within 30 days after CDI, by panel review coding, and hospital, Ontario, Canada, April 2007–February 
2008*
Reference
category† 
No. (%) deaths for hospital 
A within 30 d after Panel
review, 
no.
No. (%) deaths for hospital 
B within 30 d after Panel
review, 
no.
No. (%) deaths for hospitals 
A and B within 30 d after Panel
review, 
no.
Toxin-positive 
result
Clinical
onset‡
Toxin-positive 
result
Clinical
onset‡
Toxin-positive 
result
Clinical
onset‡
Directly/strongly 
attributable to CDI
17 (94) 17 (94) 18 46 (75) 51 (84) 61 63 (80) 68 (86) 79
Somewhat/ 
unrelated to CDI
8 (62) 8 (62) 13 16 (57) 18 (64) 28 24 (59) 26 (63) 41
Insufficient
information
–– – 00 1 0 0 1
Total 25 (81) 25 (81) 31 62 (69) 69  (77) 90 87 (72) 94  (78) 121
*CDI, Clostridium difficile infection. 
†Categories determined by panel review. Because panel review was considered the reference standard, panel review percentages = 100%. 
‡Because recurrent CDI is not always supported by laboratory or pathology confirmation, those patients with recurrent symptoms suggestive of CDI but 
no toxin confirmation were included by using the date of clinical onset of symptoms nearest to the date of death. Mortality Rates Attributable to Clostridium difﬁ  cile
Our  ﬁ   ndings suggest that cause of death on death 
certiﬁ  cate is an inaccurate measure of death attributable to 
CDI.  However, death from CDI within 30 days should be 
considered a feasible measure for the purposes of aggregate 
public reporting.
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